Teacher Retirement System of Texas Purchases 1,942 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Teacher Retirement System of Texas grew its position in Dynavax Technologies Co. (NASDAQ:DVAX) by 17.7% during the second quarter, HoldingsChannel reports. The firm owned 12,912 shares of the biopharmaceutical company’s stock after buying an additional 1,942 shares during the quarter. Teacher Retirement System of Texas’ holdings in Dynavax Technologies were worth $127,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Arizona State Retirement System increased its position in Dynavax Technologies by 6.7% during the second quarter. Arizona State Retirement System now owns 30,786 shares of the biopharmaceutical company’s stock worth $303,000 after acquiring an additional 1,922 shares during the period. Swiss National Bank increased its position in Dynavax Technologies by 1.7% during the first quarter. Swiss National Bank now owns 226,578 shares of the biopharmaceutical company’s stock worth $2,227,000 after acquiring an additional 3,700 shares during the period. ClariVest Asset Management LLC increased its position in Dynavax Technologies by 5.6% during the first quarter. ClariVest Asset Management LLC now owns 81,200 shares of the biopharmaceutical company’s stock worth $798,000 after acquiring an additional 4,300 shares during the period. BNP Paribas Arbitrage SA increased its position in Dynavax Technologies by 43.0% during the first quarter. BNP Paribas Arbitrage SA now owns 16,523 shares of the biopharmaceutical company’s stock worth $162,000 after acquiring an additional 4,972 shares during the period. Finally, Royal Bank of Canada increased its position in Dynavax Technologies by 33.7% during the first quarter. Royal Bank of Canada now owns 23,551 shares of the biopharmaceutical company’s stock worth $231,000 after acquiring an additional 5,941 shares during the period. 78.27% of the stock is currently owned by institutional investors.

DVAX has been the topic of a number of research reports. The Goldman Sachs Group initiated coverage on shares of Dynavax Technologies in a research report on Friday, August 6th. They set a “buy” rating and a $19.00 target price on the stock. William Blair reiterated a “buy” rating on shares of Dynavax Technologies in a research note on Friday. TheStreet upgraded shares of Dynavax Technologies from a “d-” rating to a “c-” rating in a research note on Wednesday, August 18th. Finally, HC Wainwright initiated coverage on shares of Dynavax Technologies in a research note on Wednesday, September 15th. They set a “buy” rating and a $23.00 price target on the stock. One analyst has rated the stock with a sell rating and three have issued a buy rating to the company. According to data from MarketBeat, Dynavax Technologies currently has an average rating of “Buy” and a consensus price target of $18.00.

In related news, SVP Robert Janssen sold 80,000 shares of Dynavax Technologies stock in a transaction dated Friday, August 6th. The stock was sold at an average price of $10.75, for a total value of $860,000.00. Following the completion of the transaction, the senior vice president now directly owns 6,861 shares of the company’s stock, valued at $73,755.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Andrew A. F. Hack sold 2,250,000 shares of Dynavax Technologies stock in a transaction dated Monday, August 9th. The shares were sold at an average price of $10.80, for a total value of $24,300,000.00. The disclosure for this sale can be found here. Insiders sold a total of 4,408,268 shares of company stock worth $58,580,545 in the last 90 days. 11.77% of the stock is owned by corporate insiders.

DVAX opened at $14.97 on Tuesday. Dynavax Technologies Co. has a fifty-two week low of $3.58 and a fifty-two week high of $20.40. The company has a debt-to-equity ratio of 2.64, a current ratio of 2.85 and a quick ratio of 2.43. The firm’s fifty day moving average price is $13.04 and its two-hundred day moving average price is $10.59. The company has a market capitalization of $1.72 billion, a P/E ratio of -57.58 and a beta of 1.37.

Dynavax Technologies (NASDAQ:DVAX) last issued its earnings results on Wednesday, August 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.06. Dynavax Technologies had a negative net margin of 3.37% and a negative return on equity of 7.33%. The company had revenue of $52.77 million for the quarter, compared to the consensus estimate of $44.04 million. On average, equities research analysts expect that Dynavax Technologies Co. will post 0.65 EPS for the current fiscal year.

Dynavax Technologies Company Profile

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

Recommended Story: How to execute a trade ex-dividend strategy?

Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Co. (NASDAQ:DVAX).

Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.